ClinicalTrials.gg
RecruitingNCT06386497Somnomat CasaUpdated May 22, 2026

Acceptability of the Somnomat Casa for the Treatment of Parkinson's Disease

An interventional study of Nocturnal translational vestibular stimulation in Parkinson Disease, sponsored by Insel Gruppe AG, University Hospital Bern. Recruiting at 2 sites in Switzerland. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Insel Gruppe AG, University Hospital Bern · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Jan 2024, registered Apr 2024).
  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Parkinson Disease by Insel Gruppe AG, University Hospital Bern — 6 open to participants now, 7 under way, none of them phase 3. Parkinson Disease · Insel Gruppe AG, University Hospital Bern.

Started
2024
with 1 other
No phase
7 of 10
5 open now
Registered
8th of 10
by date

Among the 10 studies in Parkinson Disease by Insel Gruppe AG, University Hospital Bern, this one is one of 2 that started in 2024, is one of 7 with no phase, and was the 8th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

6 of the 10 studies in Parkinson Disease by Insel Gruppe AG, University Hospital Bern are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Parkinson Disease by Insel Gruppe AG, University Hospital Bern, or all of them as a file.
02

Study summary

This pilot study aims to evaluate the feasibility and acceptability of nocturnal translational vestibular stimulations (VS) applied by a rocking bed (Somnomat Casa) for two months in patients with Parkinson's Disease.

Read the detailed description

Twelve PD patients will receive overnight VS in their familiar home environment for two months via the rocking bed. Participants will be given questionnaires to obtain feedback on the acceptability of the nocturnal intervention device.

Effects on sleep, motor and non-motor symptoms, and quality of life will be assessed using the appropriate validated scales and questionnaires. The corresponding assessments will be performed before, during, and two month after the intervention.

Unobtrusive pressure-sensitive textiles and bioradar will be used to record physiological variables such as body position, movements, breathing rate, and heart rate to correlate them to the clinical assessments as well as to markers obtained from actigraphy devices that the patients will be wearing throughout the study.

The primary feasibility outcomes include rate of accrual and retention, adherence to the protocol, acceptability and satisfaction with intervention using rocking bed specific questionnaires, semi-structured interviews, and data collected automatically from the bed.

To assess the preliminary effectiveness of the intervention the secondary outcomes are the change in subjective sleep quality, daytime sleepiness, PD related sleep disorders, mentation, behaviour, mood, activities of daily living, motor performance, and quality of life.

03

Conditions studied

  • Parkinson Disease

Keywords

  • Vestibular Stimulation
  • Sleep quality
  • Rocking bed
  • Feasibility
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • signed by the subject
  • PD according to the MDS clinical diagnostic criteria for Parkinson's disease
  • Suffering from reduced sleep quality as defined by pathological cut-off (score of > 5) on the Pittsburgh Sleep Quality Index (PSQI)
  • Patients with stable antiparkinsonian, antidepressant, and sleep medications for six weeks before intervention and maintained on stable medication during the intervention period
  • Treatment without bilateral deep brain stimulation
  • Fluent in German

Exclusion criteria

Exclusion Criteria:

  • Brain disease other than Parkinson's disease (e.g. atypical Parkinsonism, Alzheimer's disease, vascular dementia, multiple sclerosis, stroke, traumatic brain injury, epilepsy, etc.).
  • Dementia as defined by a MOCA score lower than 24/30
  • Weight > 150kg
  • Depression with acute suicidal ideation
  • Presence of major ongoing psychiatric illness such as acute non-controlled psychosis
  • Poor general health (e.g. non-controlled diabetes, uncontrolled arterial hypertension, therapy for )
  • Inability to follow the procedures of the study, e.g. filling out patient questionnaires due to language problems, psychological disorders, dementia, etc. of the participant
  • Participation in another interventional trial within the 30 days preceding and during the present study
  • Participants with PSQI score lower or equal 5
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Parkinson's disease patients

    All included Parkinson's disease patients

    Device: Nocturnal translational vestibular stimulation

Interventions

  • DeviceNocturnal translational vestibular stimulation

    Nocturnal (overnight) translational vestibular stimulation applied by the rocking bed (Somnomat Casa) for two months in patients familiar home environment.

06

What researchers measure

Primary outcomes

  1. Evaluation of acceptability and feasibility

    The acceptability and feasibility of the translational vestibular stimulation with the Somnomat Casa will be evaluated with a custom-designed questionnaire. The questionnaire consists of 22 questions including questions with five-point likert scale and open questions ("I fully agree" to "I do not agree at all").

    Time frame: At Visit 1 (1 month after start of intervention)

  2. Evaluation of acceptability and feasibility

    The acceptability and feasibility of the translational vestibular stimulation with the Somnomat Casa will be evaluated with a custom-designed questionnaire. The questionnaire consists of 22 questions including questions with five-point likert scale and open questions ("I fully agree" to "I do not agree at all").

    Time frame: At Visit 2, at the end of the intervention (after 2 months)

Secondary outcomes

  1. Pittsburgh Sleep Quality Index (PSQI)

    The PSQI is a self-report questionnaire that assesses sleep quality over a 1-month time interval. The measure consists of 19 individual items, assessing a broad range of domains associated with sleep quality, including: usual sleep wake patterns, duration of sleep, sleep latency, the frequency and severity of specific sleep-related problems, and the perceived impact of poor sleep on daytime functioning.

    Time frame: At Baseline Visit (before the intervention)

  2. Pittsburgh Sleep Quality Index (PSQI)

    The PSQI is a self-report questionnaire that assesses sleep quality over a 1-month time interval. The measure consists of 19 individual items, assessing a broad range of domains associated with sleep quality, including: usual sleep wake patterns, duration of sleep, sleep latency, the frequency and severity of specific sleep-related problems, and the perceived impact of poor sleep on daytime functioning.

    Time frame: At Visit 1 (1 month after start of intervention)

  3. Pittsburgh Sleep Quality Index (PSQI)

    The PSQI is a self-report questionnaire that assesses sleep quality over a 1-month time interval. The measure consists of 19 individual items, assessing a broad range of domains associated with sleep quality, including: usual sleep wake patterns, duration of sleep, sleep latency, the frequency and severity of specific sleep-related problems, and the perceived impact of poor sleep on daytime functioning.

    Time frame: At Visit 2, at the end of the intervention (after 2 months)

  4. Pittsburgh Sleep Quality Index (PSQI)

    The PSQI is a self-report questionnaire that assesses sleep quality over a 1-month time interval. The measure consists of 19 individual items, assessing a broad range of domains associated with sleep quality, including: usual sleep wake patterns, duration of sleep, sleep latency, the frequency and severity of specific sleep-related problems, and the perceived impact of poor sleep on daytime functioning.

    Time frame: At Final Visit (two months after the intervention)

  5. Epworth Sleepiness Scale (ESS)

    The ESS is a short self-administered questionnaire designed to assess daytime sleepiness. This basic test involves a self-assessment of how likely a person is to fall asleep in eight different situations.

    Time frame: At Baseline Visit (before the intervention)

  6. Epworth Sleepiness Scale (ESS)

    The ESS is a short self-administered questionnaire designed to assess daytime sleepiness. This basic test involves a self-assessment of how likely a person is to fall asleep in eight different situations.

    Time frame: At Visit 1 (1 month after start of intervention)

  7. Epworth Sleepiness Scale (ESS)

    The ESS is a short self-administered questionnaire designed to assess daytime sleepiness. This basic test involves a self-assessment of how likely a person is to fall asleep in eight different situations.

    Time frame: At Visit 2, at the end of the intervention (after 2 months)

  8. Epworth Sleepiness Scale (ESS)

    The ESS is a short self-administered questionnaire designed to assess daytime sleepiness. This basic test involves a self-assessment of how likely a person is to fall asleep in eight different situations.

    Time frame: At Final Visit (two months after the intervention)

  9. Parkinson's Disease Sleep Scale version 2 (PDSS-2)

    The PDSS-2 is a patient-completed clinical rating scale that assesses the frequency of sleep disturbances over the past week. The PDSS-2 covers three domains: motor symptoms at night, PD specific symptoms at night and disturbed sleep.

    Time frame: At Baseline Visit (before the intervention)

  10. Parkinson's Disease Sleep Scale version 2 (PDSS-2)

    The PDSS-2 is a patient-completed clinical rating scale that assesses the frequency of sleep disturbances over the past week. The PDSS-2 covers three domains: motor symptoms at night, PD specific symptoms at night and disturbed sleep.

    Time frame: At Visit 1 (1 month after start of intervention)

  11. Parkinson's Disease Sleep Scale version 2 (PDSS-2)

    The PDSS-2 is a patient-completed clinical rating scale that assesses the frequency of sleep disturbances over the past week. The PDSS-2 covers three domains: motor symptoms at night, PD specific symptoms at night and disturbed sleep.

    Time frame: At Visit 2, at the end of the intervention (after 2 months)

  12. Parkinson's Disease Sleep Scale version 2 (PDSS-2)

    The PDSS-2 is a patient-completed clinical rating scale that assesses the frequency of sleep disturbances over the past week. The PDSS-2 covers three domains: motor symptoms at night, PD specific symptoms at night and disturbed sleep.

    Time frame: At Final Visit (two months after the intervention)

  13. Restless Legs Syndrome Rating Scale (IRLS)

    IRLS is a 10-item questionnaire to assess the severity of the Restless Legs Syndrome (RLS).

    Time frame: At Baseline Visit (before the intervention)

  14. Restless Legs Syndrome Rating Scale (IRLS)

    IRLS is a 10-item questionnaire to assess the severity of the Restless Legs Syndrome (RLS).

    Time frame: At Visit 1 (1 month after start of intervention)

  15. Restless Legs Syndrome Rating Scale (IRLS)

    IRLS is a 10-item questionnaire to assess the severity of the Restless Legs Syndrome (RLS).

    Time frame: At Visit 2, at the end of the intervention (after 2 months)

  16. Restless Legs Syndrome Rating Scale (IRLS)

    IRLS is a 10-item questionnaire to assess the severity of the Restless Legs Syndrome (RLS).

    Time frame: At Final Visit (two months after the intervention)

  17. Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS)

    The MDS-UPDRS is a scale used to measure the severity of PD. A higher score denotes greater disability. It includes four parts: mentation, behaviour and mood (MDS-UPDRS I); activities of daily living (MDS-UPDRS II); motor examination MDS-UPDRS III); complication of treatment (MDS-UPDRS IV).

    Time frame: At Baseline Visit (before the intervention)

  18. Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS)

    The MDS-UPDRS is a scale used to measure the severity of PD. A higher score denotes greater disability. It includes four parts: mentation, behaviour and mood (MDS-UPDRS I); activities of daily living (MDS-UPDRS II); motor examination MDS-UPDRS III); complication of treatment (MDS-UPDRS IV).

    Time frame: At Visit 1 (1 month after start of intervention)

  19. Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS)

    The MDS-UPDRS is a scale used to measure the severity of PD. A higher score denotes greater disability. It includes four parts: mentation, behaviour and mood (MDS-UPDRS I); activities of daily living (MDS-UPDRS II); motor examination MDS-UPDRS III); complication of treatment (MDS-UPDRS IV).

    Time frame: At Visit 2, at the end of the intervention (after 2 months)

  20. Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS)

    The MDS-UPDRS is a scale used to measure the severity of PD. A higher score denotes greater disability. It includes four parts: mentation, behaviour and mood (MDS-UPDRS I); activities of daily living (MDS-UPDRS II); motor examination MDS-UPDRS III); complication of treatment (MDS-UPDRS IV).

    Time frame: At Final Visit (two months after the intervention)

  21. Parkinson's disease quality of life questionnaire (PDQ-39)

    The Parkinson's disease quality of life questionnaire evaluates the disease specific QoL. This questionnaire quantifies disease-specific and disease-referred quality of life in PD patients. In 39 items 8 main dimensions are interrogated (mobility, activities of daily living, emotional well-being, stigma, social support, cognitive impairment, communication and bodily discomfort). Each of these 8 domains contributes equally to a summary index of overall disease specific QoL.

    Time frame: At Baseline Visit (before the intervention)

  22. Parkinson's disease quality of life questionnaire (PDQ-39)

    The Parkinson's disease quality of life questionnaire evaluates the disease specific QoL. This questionnaire quantifies disease-specific and disease-referred quality of life in PD patients. In 39 items 8 main dimensions are interrogated (mobility, activities of daily living, emotional well-being, stigma, social support, cognitive impairment, communication and bodily discomfort). Each of these 8 domains contributes equally to a summary index of overall disease specific QoL.

    Time frame: At Visit 1 (1 month after start of intervention)

  23. Parkinson's disease quality of life questionnaire (PDQ-39)

    The Parkinson's disease quality of life questionnaire evaluates the disease specific QoL. This questionnaire quantifies disease-specific and disease-referred quality of life in PD patients. In 39 items 8 main dimensions are interrogated (mobility, activities of daily living, emotional well-being, stigma, social support, cognitive impairment, communication and bodily discomfort). Each of these 8 domains contributes equally to a summary index of overall disease specific QoL.

    Time frame: At Visit 2, at the end of the intervention (after 2 months)

  24. Parkinson's disease quality of life questionnaire (PDQ-39)

    The Parkinson's disease quality of life questionnaire evaluates the disease specific QoL. This questionnaire quantifies disease-specific and disease-referred quality of life in PD patients. In 39 items 8 main dimensions are interrogated (mobility, activities of daily living, emotional well-being, stigma, social support, cognitive impairment, communication and bodily discomfort). Each of these 8 domains contributes equally to a summary index of overall disease specific QoL.

    Time frame: At Final Visit (two months after the intervention)

  25. Patients' Global Impression of Severity Scale (PGIS)

    The Patient Global Impression of Severity scale is a single, self-administered question asking respondents about the severity of their current general condition.

    Time frame: At Baseline Visit (before the intervention)

  26. Patients' Global Impression of Change Scale (PGICS)

    The Patient Global Impression of Change scale is a single, self-administered question asking respondents to rate how their condition has changed since a certain point in time.

    Time frame: At Visit 1 (1 month after start of intervention)

  27. Patients' Global Impression of Change Scale (PGICS)

    The Patient Global Impression of Change scale is a single, self-administered question asking respondents to rate how their condition has changed since a certain point in time.

    Time frame: At Visit 2, at the end of the intervention (after 2 months)

  28. Patients' Global Impression of Change Scale (PGICS)

    The Patient Global Impression of Change scale is a single, self-administered question asking respondents to rate how their condition has changed since a certain point in time.

    Time frame: At Final Visit (two months after the intervention)

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Dec 2027, 47 months after the start.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 47 months is above that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2024
First posted
Apr 26, 2024
StartActual
Jan 11, 2024
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06386497
Collaborators
ETH Zurich
Responsible party
Sponsor
First posted
Apr 26, 2024
Start date
Jan 11, 2024
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
May 22, 2026

Study contacts

Lenard Lachenmayer, MD
Contact
lenard.lachenmayer@insel.ch
31 66 4 12 59 ext. +41
Lenard Lachenmayer, MD
principal investigator · Insel Gruppe AG, University Hospital Bern

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion